story of the week
MK-6482 as a Potential Treatment for VHL Disease-Associated Clear Cell RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Expert Opinion on Investigational Drugs
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MK-6482 as a Potential Treatment for von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Expert Opin Investig Drugs 2021 May 04;[EPub Ahead of Print], E Hasanov, E JonaschFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.